61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

Key Takeaways Explain This Topic AI

Chronic tinnitus (>3 months) is categorized as primary (idiopathic sensorineural, non-pulsatile, associated with cochlear hair cell loss and central auditory cortical hyperactivity) or secondary; cognitive behavioral therapy (CBT) and hearing aids provide the highest level of clinical evidence for symptom relief and distress reduction, whereas routine pharmacotherapy is ineffective and not recommended.

Unilateral tinnitus accompanied by asymmetric sensorineural hearing loss is a major red flag for Vestibular Schwannoma (Acoustic Neuroma) arising from the vestibular branch of CN VIII at the cerebellopontine angle; high-resolution Brain MRI with internal auditory canal (IAC) protocol and gadolinium contrast is the definitive diagnostic gold standard.

Pulsatile tinnitus—rhythmic sound synchronous with the patient's heartbeat—reflects vascular etiology (dural arteriovenous fistula, carotid stenosis, glomus jugulare tumor) or Idiopathic Intracranial Hypertension (IIH / pseudotumor cerebri), which characteristically presents in young obese females with daily headache, papilledema, transient visual obscurations, and opening pressure >250 mm H2O on lumbar puncture.

Presbycusis is an age-related, symmetric, bilateral high-frequency sensorineural hearing loss caused by degeneration of hair cells in the basal turn of the organ of Corti; clinical hallmarks include difficulty understanding speech in noisy environments ('cocktail party effect'), loss of high-frequency consonants (s, f, th, p), normal tympanometry, and a down-sloping audiogram, managed with bilateral digital hearing aids and assistive devices.

Persistent Postural-Perceptual Dizziness (PPPD) is a chronic functional vestibular disorder characterized by non-spinning dizziness, unsteadiness, or swaying present on most days for >=3 months, exacerbated by upright posture, active/passive motion, and visually complex environments (supermarkets, crowds); physical examination and vestibular testing are normal, and management combines vestibular rehabilitation therapy (VRT), SSRIs/SNRIs, and CBT.

Last updated: September 2026

Chronic Tinnitus: Classification, Pathophysiology & Red Flags

Tinnitus is defined as the perception of sound (ringing, buzzing, hissing, whistling, humming, clicking, or roaring) in the absence of an external auditory stimulus. It is classified as chronic when it persists for > 3 months >3\text{ months} > 3 months . In the United States, chronic tinnitus affects approximately 10% to 15% of the adult population, with 20% to 25% of affected individuals experiencing clinically significant functional impairment, severe sleep disruption, anxiety, or depression.

Primary vs. Secondary Tinnitus

Primary (Sensorineural) Tinnitus : Idiopathic, non-pulsatile, continuous tinnitus that is almost universally associated with underlying sensorineural hearing loss (SNHL). Cochlear hair cell loss (from presbycusis or noise trauma) diminishes afferent sensory input to the central auditory pathways. In response to this auditory deafferentation, the central nervous system undergoes maladaptive neuroplastic reorganization within the dorsal cochlear nucleus, inferior colliculus, and primary auditory cortex. The brain increases central neuronal gain, develops spontaneous synchronized hyperactivity, and establishes hyperconnectivity between the auditory cortex and the limbic system (amygdala, insula) . This limbic involvement attaches emotional salience, autonomic distress, and vigilance to the phantom percept—analogous to phantom limb pain.

Secondary Tinnitus : Tinnitus directly attributable to an identifiable underlying organic, mechanical, vascular, or structural otologic disorder (e.g., cerumen impaction, otitis media, otosclerosis, eustachian tube dysfunction, temporomandibular joint [TMJ] syndrome, vestibular schwannoma, or vascular malformations). DIAGNOSTIC TRIAGE OF TINNITUS: LATERALITY & RHYTHMICITY

Tinnitus Presentation Underlying Pathophysiology Mandatory Diagnostic Investigation

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Bilateral, Non-Pulsatile, Cochlear hair cell degeneration Comprehensive Audiometry;

High-Pitched Ringing (Presbycusis, chronic noise exposure) No neuroimaging required if symmetric.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
UNILATERAL Non-Pulsatile RED FLAG FOR RETROCOCHLEAR LESION: BRAIN MRI with Internal Auditory Canal
Tinnitus with Asymmetric Vestibular Schwannoma (Acoustic Neuroma) (IAC) protocol WITH GADOLINIUM;

Sensorineural Hearing Loss compressing CN VIII in cerebellopontine mandatory gold standard.

angle (CPA)
───────────────────────────────────────────────────────────────────────────────────────────────────────────
PULSATILE Tinnitus Vascular turbulent flow or elevated CTA or MRA/MRV of Head and Neck;
(Synchronous with pulse; intracranial pressure: dAVF, carotid Fundoscopic exam (papilledema);
'whooshing' heartbeat sound) stenosis, glomus tumor, or IDIOPATHIC Lumbar puncture for opening pressure

INTRACRANIAL HYPERTENSION (IIH) (if IIH suspected).

High-Yield Red Flags in Tinnitus Evaluation

Unilateral Tinnitus with Asymmetric Sensorineural Hearing Loss :

Vestibular Schwannoma (Acoustic Neuroma) : A benign, slow-growing Schwann cell neoplasm originating from the superior or inferior vestibular branch of the eighth cranial nerve (CN VIII) within the internal auditory canal and cerebellopontine angle.

Clinical Hallmarks : Progressive, unilateral high-frequency sensorineural hearing loss; unilateral non-pulsatile tinnitus; and poor speech discrimination (disproportionately impaired word recognition relative to pure-tone thresholds). Mild unsteadiness may occur, but true rotational vertigo is rare due to gradual central vestibular compensation.

Advanced Signs : Large tumors ( > 2 − 3 cm >2-3\text{ cm} > 2 − 3 cm ) compress adjacent structures: trigeminal nerve (CN V) causing ipsilateral facial hypesthesia or an absent corneal reflex; facial nerve (CN VII) causing mild facial paresis; cerebellum causing limb ataxia; and fourth ventricle compression causing hydrocephalus.

Diagnostic Gold Standard : Magnetic Resonance Imaging (MRI) of the Brain and Internal Auditory Canals (IACs) with thin-slice sequences and IV gadolinium contrast . High sensitivity can detect micro-schwannomas as small as 1 to 2 mm.

Pulsatile Tinnitus :

Tinnitus described as a rhythmic pulsing, clicking, or whooshing sound that matches the patient's arterial heartbeat is almost always secondary to an identifiable vascular or intracranial disorder:

Dural Arteriovenous Fistula (dAVF) or Arteriovenous Malformation (AVM) : Abnormal direct arteriovenous shunts; carries a high risk of intracranial hemorrhage; requires CTA, MRA, or digital subtraction catheter angiography.

Carotid Artery Stenosis or Dissection : Turbulent arterial flow transmitted through the temporal petrous bone.

Paragangliomas (Glomus Tumors) : Glomus tympanicum (middle ear) or Glomus jugulare (jugular bulb); hypervascular neuroendocrine tumors. Otoscopy classically reveals a pulsatile, reddish-blue retro-tympanic mass behind an intact tympanic membrane.

Idiopathic Intracranial Hypertension (IIH / Pseudotumor Cerebri) : Elevated intracranial pressure transmitted to the dural venous sinuses produces turbulent venous flow, perceived as pulsatile tinnitus (see below).

Idiopathic Intracranial Hypertension (IIH)

Epidemiology : Predominantly affects young, overweight or obese women of childbearing age (female-to-male ratio 8 : 1 8:1 8 : 1 ; BMI ≥ 30 kg/m 2 \ge 30\text{ kg/m}^2 ≥ 30 kg/m 2 ).

Clinical Presentation :

Holocephalic, daily, throbbing headache that worsens upon waking, recumbency, or Valsalva maneuvers (coughing, bending over).

Pulsatile tinnitus described as a 'washing machine' or rhythmic whooshing synchronous with the heartbeat.

Transient visual obscurations (TVOs) : Brief episodes (lasting seconds) of partial or complete visual dimming or blackout, typically provoked by standing or bending.

Horizontal diplopia due to unilateral or bilateral abducens nerve (CN VI) palsy (a non-localizing false localizing sign caused by downward traction of the long intracranial course of CN VI across the petrous ridge).

Physical Examination : Fundoscopy reveals bilateral papilledema (optic disc elevation, blurred margins, loss of physiological venous pulsations, flame hemorrhages).

Diagnostic Protocol :

Neuroimaging : Brain MRI with MR Venography (MRV) must precede lumbar puncture. Confirms absence of space-occupying lesions or cerebral venous sinus thrombosis. Classic neuroimaging findings of IIH include an empty sella turcica , flattening of the posterior sclera, distension of the perioptic subarachnoid space, and bilateral transverse venous sinus stenosis.

Lumbar Puncture : Performed in the lateral decubitus position; demonstrates an elevated opening pressure > 250 mm H 2 O >250\text{ mm H}_2\text{O} > 250 mm H 2 O ( > 25 cm H 2 O >25\text{ cm H}_2\text{O} > 25 cm H 2 O ) with completely normal CSF cytological and biochemical composition.

Management :

Weight loss (a 5 − 10 % 5-10\% 5 − 10% reduction in total body weight is disease-modifying and induces remission).

Carbonic anhydrase inhibitors: Acetazolamide ( 500 − 2000 mg/day 500-2000\text{ mg/day} 500 − 2000 mg/day in divided doses) reduces CSF production at the choroid plexus.

Second-line: Topiramate (promotes weight loss and has mild carbonic anhydrase activity).

Surgical Interventions: For progressive visual field loss refractory to medical therapy: optic nerve sheath fenestration (ONSF) to preserve vision, or CSF shunting (ventriculoperitoneal or lumboperitoneal shunt).

Evidence-Based Management of Primary Tinnitus

The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) clinical practice guidelines emphasize an evidence-based approach:

Comprehensive Audiometry : Mandatory initial test for all patients with persistent tinnitus to establish hearing thresholds and detect asymmetry.

Bilateral Digital Hearing Aids : Recommended for patients with tinnitus accompanied by documented hearing loss. Amplification of ambient background environmental sounds elevates background acoustic input, masking the tinnitus signal and reducing central gain.

Cognitive Behavioral Therapy (CBT) : Highest level of clinical evidence (Grade A) . While CBT does not reduce the physical decibel volume of tinnitus, it systematically restructures catastrophic cognitions, desensitizes limbic hyperarousal, improves coping mechanisms, and relieves associated insomnia and depression.

Sound Masking & Sound Therapy : Desktop white-noise generators, wearable sound generators, or smartphone sound applications provide pleasant ambient masking sound to reduce the contrast between the tinnitus and quiet environments.

Pharmacotherapy is NOT Recommended : Extensive clinical trials demonstrate that antidepressants, anticonvulsants (gabapentin), ginkgo biloba, zinc, melatonin, and transcranial magnetic stimulation provide no benefit over placebo . The AAO-HNS explicitly recommends AGAINST routine pharmacotherapy for primary tinnitus.

Presbycusis (Age-Related Hearing Loss)

Presbycusis is the most common sensory impairment in older adults, affecting over one-third of individuals aged 65 to 74 years and over half of those aged 75 and older. It represents a progressive, symmetrical, bilateral sensorineural hearing loss resulting from cumulative physiological aging, genetic susceptibility, environmental acoustic trauma, and microvascular strain. SCHUKNECHT HISTOPATHOLOGICAL CLASSIFICATION OF PRESBYCUSIS

Presbycusis Subtype Primary Anatomical Site of Pathology Audiometric Profile & Clinical Hallmark

Sensory Presbycusis Atrophy & loss of outer hair cells in Steeply down-sloping high-frequency SNHL;

the BASAL TURN of the organ of Corti speech discrimination preserved if quiet.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Neural Presbycusis Atrophy of cochlear spiral ganglion Down-sloping high-frequency loss; DISPROPORTIONATE

neurons and auditory nerve fibers loss of speech discrimination ('phonemic regression').

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Strial (Metabolic) Atrophy of the STRIA VASCULARIS FLAT sensorineural hearing loss across all

Presbycusis (loss of endolymph potential generation) frequencies; excellent speech discrimination score.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Cochlear Conductive Stiffening & calcification of the Gradually sloping high-frequency loss;

(Mechanical) basilar membrane of the cochlea middle ear mechanics completely normal.

Clinical Manifestations

Impaired Speech Understanding in Noise : The quintessential complaint is inability to understand spoken conversation in noisy, crowded acoustic environments—the 'cocktail party effect' .

Loss of High-Frequency Consonants : The human ear relies on high frequencies ( 2000 − 8000 Hz 2000-8000\text{ Hz} 2000 − 8000 Hz ) to distinguish voiceless consonant sounds ( s, f, th, sh, p, t, k ), while low frequencies ( 250 − 1000 Hz 250-1000\text{ Hz} 250 − 1000 Hz ) convey vowel sounds ( a, e, i, o, u ). Because presbycusis primarily affects high frequencies, patients retain the volume of speech but lose clarity, complaining: "I can hear people talking, but I can't understand what they are saying" or "Everyone is mumbling."

Recruitment : An abnormal, rapid increase in perceived loudness as sound intensity rises above the hearing threshold. A patient cannot hear normal conversation, but shouting is experienced as uncomfortably or painfully loud.

Bilateral High-Pitched Tinnitus : Present in up to 70% of individuals with presbycusis.

Physical Examination & Tuning Fork Tests

Otoscopy : The external auditory canals and tympanic membranes are completely normal ; rules out cerumen impaction, tympanic membrane perforation, middle ear effusion, and otosclerosis.

Weber Test (512 Hz Fork) : Placed on the midline forehead or vertex; sound is perceived centrally in the midline (equal sensation in both ears), reflecting symmetric bilateral sensorineural loss.

Rinne Test (512 Hz Fork) : Tested on the mastoid process (bone conduction) and adjacent to the ear canal (air conduction); Air Conduction > Bone Conduction bilaterally (AC > BC; Positive Rinne) . Confirms normal middle ear mechanics and rules out conductive hearing loss.

Diagnostic Audiometry

Pure-Tone Air and Bone Conduction : Demonstrates a characteristic bilateral, symmetric, down-sloping sensorineural hearing loss that starts above 1000 − 2000 Hz 1000-2000\text{ Hz} 1000 − 2000 Hz and is most pronounced at 4000 − 8000 Hz 4000-8000\text{ Hz} 4000 − 8000 Hz .

No Air-Bone Gap : Bone conduction thresholds match air conduction thresholds (air-bone gap ≤ 10 dB \le 10\text{ dB} ≤ 10 dB ).

Tympanometry : Normal Type A curve (normal middle ear compliance and atmospheric pressure). REPRESENTATIVE PURE-TONE AUDIOGRAM IN PRESBYCUSIS

Frequency (Hz) 125 250 500 1000 2000 4000 8000
Hearing Level
10 dB ───────────────────────────────────────────────────────── Normal Hearing Threshold
0 dB
10 dB
20 dB ───────[Normal]────────────────────────────────────────── Hearing Loss Threshold
30 dB ───────────────[Mild SNHL]──────────┐
40 dB │
50 dB ────────────────────────────────────┴──[Moderate SNHL]──┐
60 dB │
70 dB ────────────────────────────────────────────────────────┴──[Severe SNHL]
80 dB
90 dB
100 dB

*Graph demonstrates classic down-sloping bilateral sensorineural loss sparing low frequencies (250-1000 Hz)

with progressive, severe loss at high frequencies (4000-8000 Hz) responsible for consonant clarity.

Systemic & Cognitive Implications

Untreated hearing loss is not an isolated sensory deficit. It fosters social isolation, communication breakdown, loss of autonomy, and late-life depression. The landmark Lancet Commission on Dementia Prevention identified mid-life and late-life hearing loss as the single largest modifiable risk factor for dementia , accounting for 8% of all dementia cases worldwide. Cognitive load theory suggests that excessive mental effort spent decoding degraded acoustic signals depletes cognitive reserves required for working memory and executive function.

Clinical Management

Bilateral Digital Hearing Aids : The primary treatment modality. Modern programmable digital aids utilize multi-channel compression to selectively amplify high-frequency sounds without uncomfortably amplifying lower frequencies.

Over-The-Counter (OTC) Hearing Aids : FDA-regulated direct-to-consumer devices for adults aged ≥ 18 years \ge 18\text{ years} ≥ 18 years with perceived mild-to-moderate hearing impairment; greatly increases accessibility and affordability.

Assistive Listening Devices : Remote wireless FM microphones, television streaming adapters, pocket talkers, and amplified telephones.

Communication Tactics : Advise family members to face the patient directly in well-lit rooms, gain attention before speaking, eliminate background television or radio noise, and articulate clearly at a natural volume without shouting.

Cochlear Implantation : Indicated for older adults with severe-to-profound bilateral sensorineural loss who achieve < 50 − 60 % <50-60\% < 50 − 60% word recognition scores despite optimal digital hearing aids.

Persistent Postural-Perceptual Dizziness (PPPD)

Persistent Postural-Perceptual Dizziness (PPPD) is a chronic functional vestibular and neurological disorder recognized by the Bárány Society and the World Health Organization (ICD-11). It is the most common cause of chronic, persistent dizziness in adults aged 20 to 50 years, accounting for 15% to 20% of patients presenting to specialized vestibular centers.

Pathophysiology

PPPD represents a failure of the brain's postural control system to adapt following an acute vestibular or balance disturbance:

The Precipitating Event : An acute medical, neurological, or vestibular event (e.g., Benign Paroxysmal Positional Vertigo [BPPV], vestibular neuritis, Meniere disease, concussion, panic attack, or vasovagal syncope) triggers an acute mismatch in sensory inputs.

Maladaptive Neuro-Vestibular Processing : In a healthy individual, normal multimodality integration (visual, vestibular, and proprioceptive) is restored once the acute trigger resolves. In patients who develop PPPD, the central nervous system adopts three chronic maladaptive compensatory mechanisms:

Visual Dependence : The brain becomes pathologically over-reliant on visual cues for spatial orientation while discounting vestibular and somatosensory inputs.

High-Gain Postural Stiffening : Pathological co-contraction of axial and lower-extremity postural muscles with continuous postural hypervigilance.

Failure of Habituation : Inability of central cortical networks to filter out ambient environmental motion or self-generated motion cues.

Bárány Society Diagnostic Criteria for PPPD

All five of the following clinical criteria must be fulfilled to establish the diagnosis:

Core Symptoms : One or more symptoms of non-spinning dizziness, unsteadiness, or a sensation of rocking/swaying present on most days for ≥ 3 months \ge 3\text{ months} ≥ 3 months .

Temporal Pattern : Symptoms persist for prolonged periods (hours at a time), waxing and waning in severity throughout the day.

Three Exacerbating Factors : Symptoms are exacerbated by:

Upright posture (standing or walking).

Active or passive motion (head movements, walking, riding in a vehicle).

Complex or moving visual environments (walking through busy supermarkets, crowded shopping malls, viewing moving traffic, watching action movies, or scrolling on a computer screen).

Precipitating Trigger : The condition is precipitated by an acute balance disorder, neurological illness, or psychiatric event.

Functional Impairment : Symptoms cause clinically significant distress or impairment, and are not better accounted for by another medical or psychiatric disease.

Diagnostic Evaluation & Findings

Physical & Neurological Examination : Completely NORMAL . Cranial nerves, motor strength, cerebellar testing (finger-to-nose, heel-to-shin, rapid alternating movements), sensory testing, and standard gait examination are entirely unremarkable.

Vestibular & Neuroimaging Testing : Caloric testing, videonystagmography (VNG), rotary chair, and Brain MRI are normal (or demonstrate only a well-compensated, fully resolved prior peripheral vestibular deficit).

Multimodal Management Paradigm

Patient Education & Validation : The essential first step is communicating that PPPD is a legitimate, recognized neurobiological disorder representing a functional 'software' recalibration failure of central balance pathways rather than structural 'hardware' brain damage.

Vestibular Rehabilitation Therapy (VRT) : Highly effective; customized desensitization exercises, optokinetic visual stimulation, and balance challenges designed to habituate motion sensitivity and decouple visual dependence.

Pharmacotherapy : SSRIs (e.g., Sertraline 25-50 mg daily, Escitalopram 10 mg daily) or SNRIs (e.g., Venlafaxine XR 37.5-75 mg daily) are first-line agents. They modulate central serotonergic pathways in the vestibular nuclei and anxiety circuits, reducing motion sensitivity. They should be continued for at least 6 to 12 months.

Cognitive Behavioral Therapy (CBT) : Targets hypervigilance, health anxiety, and avoidance behaviors (such as avoiding grocery stores).

STRICT CONTRAINDICATION : Chronic vestibular suppressants ( meclizine, dimenhydrinate, benzodiazepines ) are strictly contraindicated . They blunt central neuroplastic compensation, impair vestibular recalibration, and exacerbate the chronicity of PPPD.

Clinical Contrast: Benign Paroxysmal Positional Vertigo (BPPV)

Benign Paroxysmal Positional Vertigo (BPPV) is the most common cause of acute, recurrent peripheral vertigo, accounting for up to 50% of peripheral vestibular complaints. COMPARATIVE MATRIX: PPPD VS. BPPV

Feature Persistent Postural-Perceptual Dizziness (PPPD) Benign Paroxysmal Positional Vertigo (BPPV)

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Pathophysiology Functional central balance recalibration Canalithiasis: free-floating otoconia in
failure; visual dependence & postural stiffening semicircular canal (posterior canal in >85%)
───────────────────────────────────────────────────────────────────────────────────────────────────────────
Nature of Symptoms Non-spinning dizziness, swaying, rocking, VIOLENT ROTATIONAL SPINNING VERTIGO;
unsteadiness, feeling 'on a boat' nausea, oscillopsia
───────────────────────────────────────────────────────────────────────────────────────────────────────────
Duration of Episodes Continuous / fluctuating for HOURS on most BRIEF: strictly lasts < 60 SECONDS per episode
days for >= 3 months
───────────────────────────────────────────────────────────────────────────────────────────────────────────
Provoking Factors Upright posture, motion, complex visual SPECIFIC HEAD POSITION CHANGES relative to
stimuli (supermarkets, scrolling screens) gravity (rolling over in bed, looking up/down)
───────────────────────────────────────────────────────────────────────────────────────────────────────────
Diagnostic Maneuver Dix-Hallpike is NEGATIVE; exam is normal DIX-HALLPIKE TEST POSITIVE: latency (2-10s),
torsional upbeat geotropic nystagmus (<60s)
───────────────────────────────────────────────────────────────────────────────────────────────────────────
Definitive Treatment Vestibular rehabilitation therapy (VRT), EPLEY MANEUVER (Canalith Repositioning);
SSRIs/SNRIs, and Cognitive Behavioral Therapy >85-90% cure rate in 1-2 sessions;
(Meclizine is CONTRAINDICATED) (Meclizine has NO ROLE)

Pathophysiology & Diagnosis of BPPV

Canalithiasis : Otoconia (calcium carbonate crystals) detach from the otolithic membrane of the utricle and migrate into a semicircular canal—most commonly the posterior semicircular canal ( > 85 − 90 % >85-90\% > 85 − 90% of cases). When the head moves relative to gravity, the heavy otoconia move within the canal, creating hydrodynamic drag on the endolymph that deflects the cupula and triggers intense, false rotational signals.

The Dix-Hallpike Maneuver : The definitive diagnostic gold standard for posterior canal BPPV:

The patient sits upright on the examination table with the head turned 45 ∘ 45^\circ 4 5 ∘ toward the ear being tested.

The patient is rapidly moved to the supine position with the head extending 20 ∘ 20^\circ 2 0 ∘ below the table edge while maintaining the 45 ∘ 45^\circ 4 5 ∘ head turn.

Positive Test Criteria :

Latency Period : 2 to 10 seconds elapse before vertigo and nystagmus begin.

Classic Nystagmus : A paroxysmal, crescendo-decrescendo torsional (rotational) and upbeat geotropic nystagmus (the upper pole of the eye beats toward the dependent ground and forehead).

Duration : The vertigo and nystagmus fatigue and resolve in < 60 seconds <60\text{ seconds} < 60 seconds .

Fatigability : Immediate repetition of the maneuver produces diminished vertigo and nystagmus.

Definitive Management: The Epley Maneuver

Posterior canal BPPV is treated mechanically with the Epley maneuver (Canalith Repositioning Procedure) :

A 4-step sequence of head positions ( 45 ∘ 45^\circ 4 5 ∘ head turn supine → \rightarrow → head rotated 90 ∘ 90^\circ 9 0 ∘ to contralateral side → \rightarrow → patient rolls onto shoulder with head turned 45 ∘ 45^\circ 4 5 ∘ toward the floor → \rightarrow → patient returned to upright sitting).

Each position is held for 30 to 60 seconds (or until nystagmus ceases). Gravity guides the otoconia out of the posterior semicircular canal back into the utricle, where they are reabsorbed by dark cells.

Efficacy : The Epley maneuver cures posterior canal BPPV in > 85 % >85\% > 85% to 90% of patients after 1 to 2 sessions. Routine vestibular suppressants (meclizine) have no role and should not be prescribed.